MindImmune Therapeutics
Latest round
- Series A
Last raised
- Nov 2025
Total raised
- $28M
Investors
- 7
About MindImmune Therapeutics
Based in Rhode Island, US, and founded in 2016 by CEO Stevin Zorn, CSO Frank Menniti, and Robert Nelson, MindImmune Therapeutics, Inc. is a medical research firm that conducts multiple programs to develop breakthrough therapeutics for Alzheimer's disease. The company's research is guided by human and animal model genetics, which leads the company to find that cells of the peripheral immune system enter and cause damage to neurons afflicted with Alzheimer’s pathology. In November 2025, MindImmune Therapeutics, Inc. The company is developing a novel therapeutic antibody to prevent these immune cells from entering the brain, aiming to ameliorate cognitive symptoms and slow disease progression. MindImmune’s flagship program focuses on Alzheimer's disease, where innate immune cells are identified as infiltrating the brain and causing synaptic damage.
Who invested in MindImmune Therapeutics
7 investors across 4 rounds
See all investors in MindImmune Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about MindImmune Therapeutics
Who invested in MindImmune Therapeutics?
MindImmune Therapeutics has 7 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has MindImmune Therapeutics raised?
MindImmune Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did MindImmune Therapeutics last raise money?
MindImmune Therapeutics's most recent round on record is a Series A, in Nov 2025.
What does MindImmune Therapeutics do?
Based in Rhode Island, US, and founded in 2016 by CEO Stevin Zorn, CSO Frank Menniti, and Robert Nelson, MindImmune Therapeutics, Inc.
Where is MindImmune Therapeutics headquartered?
MindImmune Therapeutics is headquartered in Kingston, US.
Which VCs invest in companies like MindImmune Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at MindImmune Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like MindImmune Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.